Neuroscientific Biopharmaceuticals (ASX:NSB) — Material Events
ASX:NSB · 10 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
NeuroScientific’s StemSmart™ Shows Promise in Tough Crohn’s CasesMedium
NeuroScientific reports positive clinical responses in Crohn's disease patients treated with StemSmart™ under Special Access Program
13 Jan 2026
·ASX Announcement
·85
StemSmart™ MSC Therapy Revives Hope in Renal Transplant PatientsMedium
StemSmart™ MSC Therapy Shows Promise in Early Renal Transplant Studies
27 Aug 2025
·Clinical Study Update
·85
NeuroScientific Advances StemSmart Tech with Crohn’s Trial and $3.5M RaiseMedium
NeuroScientific completes StemSmart acquisition, advances Crohn’s and GVHD programs, raises $3.5M
23 July 2025
·Quarterly Activity Report and Appendix 4C
·85
NeuroScientific Advances StemSmart Clinical Program and Manufacturing Scale-UpMedium
NeuroScientific reports positive StemSmart clinical results, advances manufacturing and Phase 2 trial plans
30 Apr 2026
·Quarterly Activities Report
·85
NeuroScientific Advances StemSmart™ Trials with New Leadership and Manufacturing Scale-UpMedium
NeuroScientific advances StemSmart™ clinical program and leadership; $6.9M cash at Q1 FY26
30 Oct 2025
·Quarterly Activity Report
·80
NeuroScientific Taps Nathan Smith to Drive StemSmart Cell Therapy ForwardMedium
NeuroScientific Appoints Nathan Smith as CEO to Accelerate Cell Therapy Development
28 July 2025
·Executive Appointment
·75
NeuroScientific Advances StemSmart™ Therapy with Fourth Patient TreatmentMedium
NeuroScientific Treats Fourth Patient Under Special Access Scheme, Progressing StemSmart™ Phase 2 Trial
11 Nov 2025
·ASX Announcement
·75
NeuroScientific Reports Early Success in StemSmart™ Crohn’s Treatment ProgramMedium
NeuroScientific advances StemSmart™ clinical program with positive patient responses and strong cash position
30 Jan 2026
·Quarterly Activity Report
·75
NeuroScientific Posts $1.85M Loss Amid StemSmart™ Acquisition and Clinical PushMedium
NeuroScientific reports $1.85M loss, completes Isopogen acquisition, advances StemSmart™ clinical program
28 Aug 2025
·Appendix 4E and Annual Report
·Unexpected
·75
No articles in this tier for the last 12 months.
Market Mentions
3
- appeared in market wrap coverage
These are market wrap articles where Neuroscientific Biopharmaceuticals (ASX:NSB) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026
Market Wrap - Week 3 (12 Jan -> 16 Jan) 2026
18 Jan 2026